Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity

New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.